Organization Profile

You just read:

Health Canada approves VITRAKVI® (larotrectinib), the first tumour agnostic cancer treatment for advanced solid tumours harbouring an NTRK gene fusion

News provided by

Bayer Inc.

Jul 30, 2019, 09:00 ET